Insider Transactions in Q1 2024 at Elevance Health, Inc. (ELV)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 08
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Open market or private sale
|
Direct |
2,432
-13.31%
|
$1,216,000
$500.46 P/Share
|
|
Mar 06
2024
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
916
-34.18%
|
$461,664
$504.58 P/Share
|
|
Mar 04
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Open market or private sale
|
Direct |
21,095
-20.02%
|
$10,547,500
$500.18 P/Share
|
|
Mar 04
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+27.28%
|
$2,490,000
$166.97 P/Share
|
|
Mar 01
2024
|
Blair Williams Todt EVP, CLO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
8,691
+22.23%
|
-
|
|
Mar 01
2024
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,650
-30.13%
|
$1,821,350
$499.11 P/Share
|
|
Mar 01
2024
|
Ronald W Penczek CAO & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,272
+20.11%
|
-
|
|
Mar 01
2024
|
Ronald W Penczek CAO & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
383
-21.38%
|
$191,117
$499.11 P/Share
|
|
Mar 01
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+20.0%
|
-
|
|
Mar 01
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
4,314
-24.32%
|
$2,152,686
$499.11 P/Share
|
|
Mar 01
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+12.9%
|
-
|
|
Mar 01
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
4,902
-14.66%
|
$2,446,098
$499.11 P/Share
|
|
Mar 01
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
4,508
+11.67%
|
-
|
|
Mar 01
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-9.73%
|
$740,516
$499.11 P/Share
|
|
Mar 01
2024
|
Ratnakar Lavu EVP & Chief Digital Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,756
+38.33%
|
-
|
|
Mar 01
2024
|
Gail Boudreaux President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
42,932
+11.97%
|
-
|
|
Mar 01
2024
|
Gail Boudreaux President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,256
-14.05%
|
$9,608,744
$499.11 P/Share
|
|
Mar 01
2024
|
Mark Kaye EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,755
+10.68%
|
-
|
|
Feb 07
2024
|
Ramiro G Peru Director |
SELL
Open market or private sale
|
Direct |
753
-7.64%
|
$376,500
$500.0 P/Share
|
|
Jan 03
2024
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-3.17%
|
$190,560
$480.49 P/Share
|